Navigating tension of clinical equipoise in precision oncology trials

By Amy McKee, M.D., Chief Medical Officer & Global Head, Oncology Center of Excellence
Matthew Gordon, Vice President, Real-World Evidence Strategy
Stacy Hurt, M.H.A., M.B.A., Chief Patient Officer
Gwyn Bebb, M.D., BM, BCh, Ph.D., Senior Vice President, Global Therapeutic Area Head – Oncology
Amy Pace, ScD, Vice President, Biostatistics

45 min

Precision oncology has transformed cancer treatment, offering personalized therapies based on genetic and molecular profiles. However, as the field advances, so do the complexities.

In this roundtable discussion, Parexel experts cover diverse perspectives and explore the delicate balance in determining equipoise between standard-of-care treatments and scientific advancements in precision oncology.  This esteemed panel delves into the challenges and opportunities in navigating tensions while ensuring patient safety and scientific rigor.

Topics covered include:

  • Clinical Equipoise in Precision Oncology Trials
  • Hybrid Trial Designs
  • Regulatory Insights
  • Patient-Centric Approaches

COntributing Experts